Compare KR & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KR | TAK |
|---|---|---|
| Founded | 1883 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8B | 43.3B |
| IPO Year | N/A | N/A |
| Metric | KR | TAK |
|---|---|---|
| Price | $62.55 | $14.93 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $73.46 | N/A |
| AVG Volume (30 Days) | ★ 7.3M | 2.6M |
| Earning Date | 12-04-2025 | 01-29-2026 |
| Dividend Yield | 2.23% | ★ 3.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.16 | 0.14 |
| Revenue | ★ $147,225,000,000.00 | $29,846,840,032.00 |
| Revenue This Year | $4.12 | N/A |
| Revenue Next Year | $2.81 | $0.59 |
| P/E Ratio | ★ $54.11 | $106.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $58.12 | $12.80 |
| 52 Week High | $74.90 | $15.69 |
| Indicator | KR | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 67.77 |
| Support Level | $61.97 | $14.43 |
| Resistance Level | $63.90 | $14.66 |
| Average True Range (ATR) | 1.37 | 0.16 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 23.08 | 90.00 |
Kroger is one of the largest grocery retailers in the United States with about 2,700 stores across a portfolio of over 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The company also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.